MedTrace Logo

Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis

NCT06216028 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2024-05-24

No results posted yet for this study

Summary

The purpose of the ACCELERATE3 trial is to assess the efficacy of a single intra-articular (IA) injection of autologous BMAC, in one or both knees, compared to a single IA injection of Standard of Care (SOC) in patients with mild to severe knee OA.

Conditions

Interventions

BIOLOGICAL

Autologous Bone Marrow Aspirate Concentrate

Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)

Sponsors & Collaborators

  • CELL Technologies Inc.

    lead INDUSTRY

Principal Investigators

  • Riam Shamma, MD · CELL Technologies Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06216028 on ClinicalTrials.gov